A Phase II Study of Dose Density Regimen With Fluorouracil, Epirubicin and Cyclophosphamide at Days 1, 4 Every 14 Days With Filgrastim Support Followed by Weekly Paclitaxel in Women With Primary Breast Cancer.
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Women With Primary Breast Cancer
Interventions: DRUG: FEC (Fluorouracil, Epirubicin, Cyclophosphamide) + filgrastim + paclitaxel
Sponsor: Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori